A Phase 1 Study of LNCB74 in Advanced Solid Tumors

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

Trial Details

NCT ID
NCT06774963
Phase
PHASE1
Sponsor
NextCure, Inc.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • LNCB74
Locations (sample)
  • Newport Beach, California, United States|33.61891,-117.92895
  • Edgewood, Kentucky, United States|39.01867,-84.58189
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • The participant provides written informed consent
  • ≥ 18 years of age on day of signing informed consent.
  • Participant with histologically or cytologically confirmed diagnosis of advanced unresectable and/or metastatic solid tumors
  • A male participant must agree to use contraception and refrain from sperm donation or expecting to father a child

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →